secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-061989
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharmaceuticals Q3 net loss $14.9M; neffy NDA resubmission anticipated H1 2024
--------------------------------------------------------------------------------

- Cash, equivalents and short-term investments $241.9M as of Sep 30, 2023; operating runway ≥3 years.
- Net loss $14.9M for Q3 2023; R&D $3.0M, G&A $15.0M.
- FDA issued Complete Response Letter in Sep 2023 for neffy; repeat-dose study topline expected Q1 2024.
- NDA resubmission planned H1 2024; potential U.S. launch in H2 2024 if approved.
- European MAA decision expected Q2 2024; positive clinical results published in JACI.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000095017023061989/0000950170-23-061989-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000095017023061989/spry-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061989

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer